Plant Name: Juncus effusus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| KCNH2; | |
| EBP; HPGD; ALOX12; HSD17B10; ALOX15; ALDH1A1; USP2; MGLL; | |
| MAPK1; JAK2; | |
| ESR1; ESR2; | |
| MDM2; | |
| HTT; LMNA; HSP90AA1; MAPT; SIGMAR1; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | EBP | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase | Q15125 | CHEMBL4931 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | MGLL | Monoglyceride lipase | Q99685 | CHEMBL4191 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
| Transferase | MDM2 | p53-binding protein Mdm-2 | Q00987 | CHEMBL5023 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | HSP90AA1 | Heat shock protein HSP 90-alpha | P07900 | CHEMBL3880 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.530E-09 | 5.510E-05 | ESR1, ESR2, HPGD, HSP90AA1, HTT, JAK2, KCNH2, L3MBTL1, MAPK1, MAPT, MDM2, MGLL, USP2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 7.112E-07 | 2.996E-03 | ALOX12, ALOX15, HPGD |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.238E-06 | 2.996E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.238E-06 | 2.996E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.238E-06 | 2.996E-03 | ALOX12, ALOX15 |
| CC | GO:0016020; membrane | GO:0016020; membrane | 1.085E-06 | 2.996E-03 | ALOX12, ALOX15, CYP3A4, EBP, ESR1, HPGD, HSD17B10, HSP90AA1, HTT, JAK2, KCNH2, L3MBTL1, LMNA, MAPK1, MAPT, MDM2, MGLL, NPSR1, SIGMAR1, USP2 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.947E-06 | 3.855E-03 | HPGD, JAK2, MDM2 |
| BP | GO:0008152; metabolic process | GO:0006629; lipid metabolic process | 3.406E-06 | 5.774E-03 | ALDH1A1, ALOX12, ALOX15, CYP3A4, EBP, ESR1, HPGD, HSD17B10, MGLL |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.712E-06 | 5.774E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.712E-06 | 5.774E-03 | ALOX12, ALOX15 |
| BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 7.527E-06 | 8.626E-03 | HSP90AA1, HTT, MAPK1, MDM2, USP2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.420E-06 | 8.626E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 8.188E-06 | 8.915E-03 | CYP3A4, ESR1, ESR2, HSP90AA1, HTT, JAK2, KCNH2, MAPK1, MAPT, MDM2, USP2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.075E-06 | 1.269E-04 | MAPK1; JAK2; ESR1; ESR2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.858E-06 | 2.276E-04 | HSP90AA1; MAPK1; ESR1; ESR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.234E-04 | 4.853E-03 | HSP90AA1; MDM2; MAPK1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.573E-04 | 5.587E-03 | EBP; ALOX15; ALDH1A1; ALOX12; CYP3A4; HSD17B10; MGLL |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.436E-04 | 5.587E-03 | ALOX15; MAPK1; ALOX12 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.764E-04 | 7.027E-03 | HSP90AA1; MDM2; MAPK1; JAK2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.841E-04 | 5.587E-03 | MDM2; MAPK1; ESR1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.972E-04 | 1.045E-02 | MAPK1; MAPT; HSD17B10 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.376E-03 | 1.476E-02 | MDM2; MAPK1; ESR1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.606E-04 | 7.027E-03 | ALOX15; CYP3A4 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.228E-04 | 1.089E-02 | MDM2; MAPK1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.304E-03 | 1.812E-02 | MDM2; MAPK1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.099E-03 | 1.812E-02 | ALOX15; ALOX12 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.777E-03 | 1.748E-02 | HSP90AA1; MAPK1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.741E-03 | 1.898E-02 | MDM2; MAPK1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.304E-03 | 1.812E-02 | ALDH1A1; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.895E-03 | 1.898E-02 | MDM2; MAPK1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.895E-03 | 1.898E-02 | MAPK1; JAK2 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.461E-03 | 3.069E-02 | MAPK1; JAK2 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 5.150E-03 | 3.069E-02 | HSP90AA1; MAPK1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 6.558E-03 | 3.518E-02 | MAPK1; JAK2 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 5.461E-03 | 3.069E-02 | MAPK1; MGLL |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.033E-03 | 4.386E-02 | HSP90AA1; MDM2; MAPK1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 7.381E-03 | 3.787E-02 | MAPK1; JAK2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.025E-02 | 4.604E-02 | LMNA; MAPK1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 9.293E-03 | 4.386E-02 | MDM2; MAPK1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.054E-02 | 4.604E-02 | MAPK1; JAK2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | HSP90AA1; HSP90AA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | MDM2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2 |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; ESR1; HSP90AA1; JAK2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MDM2; MAPK1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | EBP |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HSP90AA1; JAK2 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Refractory hematological malignancies | NA | HSP90AA1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | MDM2; HSP90AA1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; JAK2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | MDM2; ESR1 |
| C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1; JAK2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MDM2 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | HSP90AA1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | JAK2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2 |
| NA: NA | Myeloproliferative neoplasm | NA | JAK2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MDM2; MDM2; MAPK1; ESR1; ESR1; HSP90AA1; JAK2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |